ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. Cost of revenue

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥8.89T
P/E ratio
57.1x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCost of revenue (Million JPY)YoY (%)
Mar 31, 20251,580,217+10.76%
Mar 31, 20241,426,678+14.68%
Mar 31, 20231,244,072+12.40%
Mar 31, 20221,106,846+11.32%
Mar 31, 2021994,308-8.76%
Mar 31, 20201,089,764+65.19%
Mar 31, 2019659,690+126.73%
Mar 31, 2018290,952-16.83%
Mar 31, 2017349,809+6.96%
Mar 31, 2016327,037+12.39%
Mar 31, 2015290,992

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat